Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|November 10, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, Stéphane Dalle, Laurent Mortier, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
Cancers|July 2, 2021
Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaOndine Becquart, Bastien Oriano, Stéphane Dalle, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
The British Journal of Dermatology|November 28, 2024
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world settingKarine Billard, Laurent Mortier, Olivier Dereure, et al.
Pageof 5